source
- FDA’s push to publish complete response letters faces legal uncertainty and possible pauseThe FDA began releasing complete response letters (CRLs) to the public last year, a move promoted as increasing transparency for drug developers, investors, and patients. However, the policy has e…
- Former staff allege LifeMD prioritized GLP-1 prescription volume over patient safetyNovo Nordisk lists telehealth firm LifeMD on its website as a provider that offers legitimate medicine sourcing and patient support for individuals seeking GLP-1 drugs such as Ozempic and Wegovy.…